Stocks · News reference
Natera shares are trading higher. The company announced that Japan's pharma and medical devices agency has approved its Signatera test as a companion diagnostic in muscle-invasive bladder cancer.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Live On CNBC, Kevin Simpson Announces Bought Natera
RBC Capital Maintains Outperform on Natera, Raises Price Target to $460
RBC Capital analyst Dan Leonard maintains Natera (NASDAQ:NTRA) with a Outperform and raises the price target from $350 to $460.